Optimal duration of therapy in HBV-related cirrhosis

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 1, 2007, Pages 2-6

  Lim, Carmen Y ^a   Kowdley, Kris V ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Chronic HBV; Hepatitis B virus; Treatment

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ENTECAVIR; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; TENOFOVIR; VIRUS DNA;

AUTOIMMUNE DISEASE; BACTERIAL PERITONITIS; BONE MARROW SUPPRESSION; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG APPROVAL; EDITORIAL; FLU LIKE SYNDROME; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER TOXICITY; LIVER TRANSPLANTATION; MENTAL DISEASE; MONOTHERAPY; MORBIDITY; MORTALITY; NEUROLOGIC DISEASE; NONHUMAN; POPULATION RESEARCH; PRACTICE GUIDELINE; PREDICTION; RISK ASSESSMENT; VARICOSIS; VIRUS LOAD; VIRUS REPLICATION;

ADENINE; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; HEALTH PLANNING GUIDELINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON-ALPHA; LAMIVUDINE; PHOSPHONIC ACIDS; POLYETHYLENE GLYCOLS;

EID: 34447577872     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm102     Document Type: Editorial

References (31)

1. World Health Organization. Hepatitis B Fact Sheet No. 204, Revised October 2000.
2. Ikeda K, Saitoh S, Suzuki Y et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28 930-8.
3. Mahoney FJ. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999; 12: 351-66.
4. Lee WM. Hepatitis B infection. N Engl J Med 1997; 337: 1733-45.
5. Yao GB. Importance of perinatal versus horizontal transmission of hepatitis B virus infection in China. Gut 1996; 38 Suppl 2: S39-42.
6. Fattovich G, Brollo L, Giustina G et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32 294-8.
7. Beasley RP, Hwang LY, Lin CC et al. Hepatocellular carcinoma and hepatitis B virus: A prospective study of 22707 men in Taiwan. Lancet 1981; 11: 1129-33.
8. Yang HI, Lu SN, Liaw YF et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-74.
9. Ikeda K, Saitoh S, Suzuki Y et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: A pilot study. Cancer 1998; 82: 827-35.
10. Perrillo RP, Brunt EM. Hepatic histologic and immunohistochemical changes in chronic hepatitis B after prolonged clearance of hepatitis B e antigen and hepatitis B surface antigen. Ann Intern Med 1991; 115: 113-5.
11. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63.
12. Honkoop P, de Man RA, Niesters HG et al. Clinical impact of lamivudine resistance in chronic hepatitis B. J Hepatol 1998; 29: 510-1.
13. Liaw YF, Chien RN, Yeh CT et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 567-72.
14. Marcellin P, Chang TT, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-16.
15. Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
16. Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20.
17. Lai CL, Rosmawati M, Lao J et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002; 123: 1831-8.
18. Janssen HL, van Zonneveld M, Senturk H et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial. Lancet 2005; 365: 123-9.
19. Marcellin P, Lau GK, Bonino F et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
20. Lau GK, Piratvisuth T, Luo KX et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
21. Chan HL, Hui AY, Wong VW et al. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology 2005; 41: 1357-64.
22. Lok AS, McMahon BJ. AASLD practice guideline. Chronic hepatitis B: update of recommendations. Hepatology 2004; 39: 857-61.
23. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45 507-39.
24. de Franchis R, Hadengue A, Lau G et al. EASL International Consensus Conference on Hepatitis B. 13-14 September 2002 Geneva Switzerland. Consensus statement (long version). J Hepatol 2003; 39 Suppl 1: S3-25.
25. Liaw YF, Leung N, Guan R et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update. Liver Int 2005; 25: 472-89.
26. Keeffe EB, Dieterich DT, Han SH et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004; 2: 87-106.
27. Keeffe EB, Dieterich DT, Han SH et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: An update. Clin Gastroenterol Hepatol 2006; 4: 936-62.
28. Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hapatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
29. Iloeje UH, Yang HI, Su J et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
30. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
31. Thomas HC, Lok AS, Carreno V et al. Comparative study of three doses of interferon-alpha 2a in chronic active hepatitis B. The International Hepatitis Trial Group. J Viral Hepat 1994; 1: 139-48.